Exbio — Research products — Antibodies — CD and related antigens — Anti-Ms LPAM-1 Purified

Anti-Ms LPAM-1 Purified

Regulatory status

RUO

Antigen

LPAM-1

Clone

DATK32

Format

Purified

Reactivity

Mouse

Application

IP, FC (QC tested), IHC(F)

Variant

0.1 mg

11-747-C100

In stock

88.00 USD

0.025 mg

11-747-C025

Delivery 1 week

44.00 USD

Variant

0.1 mg

11-747-C100

In stock

88.00 USD

0.025 mg

11-747-C025

Delivery 1 week

44.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Rat IgG2a kappa

Specificity

The rat monoclonal antibody DATK32 recognizes an extracellular epitope of integrin alpha 4 (CD49d) and integrin beta7 (Ly69) components of mouse LPAM-1 complex, which is expressed on the majority of peripheral lymphocytes, as well as on subsets of thymocytes and bone marrow cells.

Application

IP, FC (QC tested), IHC(F)

Application details

Flow cytometry: Recommended dilution: 1-4 μg/ml.

Reactivity

Mouse

Immunogen

TK1 cells

Concentration

1 mg/ml

Preparation

Purified by protein-G affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

Integrin alpha 4 beta 7, CD49d / Ly69

Antigen description

Integrin alpha 4 / beta 7 (CD49d / Ly69) , also known as LPAM-1 (Llmphocyte Peyer´s patch adhesion molecule 1), is a heterodimeric (150 kDa / 130 kDa) integrin complex which mediates lymphocyte homing to Peyer´s patch high endothelial venules and to the intestinal lamina propria. It is expressed primarily on mucosal lymphocytes, but is also present on NK cells and eosinophils. Ligands of LPAM-1 are MAdCAM-1, VCAM-1, and fibronectin, but the alpha 4 subunit (CD49d) can mediate also homotypic adhesion.

Flow cytometry surface staining pattern of murine splenocyte suspension stained using anti-mouse LPAM-1 (DATK32) purified antibody (concentration in sample 2 μg/ml) DAR APC.

Separation of murine LPAM-1 positive cells (red-filled) from LPAM-1 negative cells (black-dashed) in flow cytometry analysis (surface staining) of murine splenocyte suspension stained using anti-mouse LPAM-1 (DATK32) purified antibody (concentration in sample 2 μg/ml) DAR APC.

General references:

Reese SR, Kudsk KA, Genton L, Ikeda S: l-selectin and alpha4beta7 integrin, but not ICAM-1, regulate lymphocyte distribution in gut-associated lymphoid tissue of mice. Surgery. 2005 Feb;137(2):209-15.
PubMed

Yang Y, Cardarelli PM, Lehnert K, Rowland S, Krissansen GW: LPAM-1 (integrin alpha 4 beta 7)-ligand binding: overlapping binding sites recognizing VCAM-1, MAdCAM-1 and CS-1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides. Eur J Immunol. 1998 Mar;28(3):995-1004.
PubMed

Altevogt P, Hubbe M, Ruppert M, Lohr J, von Hoegen P, Sammar M, Andrew DP, McEvoy L, Humphries MJ, Butcher EC: The alpha 4 integrin chain is a ligand for alpha 4 beta 7 and alpha 4 beta 1. J Exp Med. 1995 Aug 1;182(2):345-55.
PubMed

Product specific references:

Priestley GV, Scott LM, Ulyanova T, Papayannopoulou T: Lack of alpha4 integrin expression in stem cells restricts competitive function and self-renewal activity. Blood. 2006 Apr 1;107(7):2959-67.
PubMed

Riedel SS, Mottok A, Brede C, Bäuerlein CA, Jordán Garrote AL, Ritz M, Mattenheimer K, Rosenwald A, Einsele H, Bogen B, Beilhack A: Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma. PLoS One. 2012;7(12):e52398.
PubMed